Long-term Safety, REMS Data, and Echo Monitoring for oHCM Therapies

Real-world experience with cardiac myosin inhibitors under Risk Evaluation and Mitigation Strategy (REMS) programs provides critical insight into the safety profile of these agents outside the controlled environment of clinical trials.

Matthew Martinez, MD, discusses a large, REMS-guided analysis of more than 6000 patients that informed his understanding of the incidence, severity, and reversibility of left ventricular ejection fraction (LVEF) decline. He now quotes patients an approximate risk of LVEF reduction on the order of 4% to 7%, while acknowledging the need for further refinement of risk prediction. The same data suggest that REMS infrastructure—though unfamiliar to many cardiologists—helps standardize monitoring and maintain appropriate safety margins in routine practice.

Mariko Harper, MD, notes that, despite the boxed warning and patient concern about heart failure, REMS registry data have shown a very low rate of clinically meaningful LVEF decline with heart failure hospitalization, approximately 0.5% among more than 11,000 patients over several years when drugs are used according to protocol. This allows her to reassure informed patients who present having read the label and online resources. Both clinicians question whether current monitoring schedules are more intensive than necessary, particularly early 4-week echocardiograms and routine 6‑month follow-up imaging in clinically stable patients on long-standing doses. They observe that most clinically meaningful changes correlate with recognized triggers such as infection, new medications, or atrial fibrillation rather than occurring unpredictably in otherwise stable individuals.

In this segment, Martinez and Harper propose a more risk-adapted approach to imaging-based surveillance, emphasizing symptom-triggered assessment and targeted evaluation in higher-risk periods while potentially de-emphasizing rigid time-based echocardiography in stable patients. They also describe how patient-reported symptoms usually precede concerning echocardiographic findings, suggesting that well-structured clinical follow-up and patient education may be at least as important as frequent imaging. Their discussion highlights how REMS-generated data can both reinforce the value of structured safety programs and guide thoughtful simplification of monitoring protocols over time.